 |
市场调查报告书
商品编码
1481298
皮质类固醇市场规模 - 按产品（糖皮质激素、盐皮质激素）、给药途径（局部、注射、口服、吸入）、应用（皮肤过敏、风湿病适应症）、配销通路和预测，2024 - 2032Corticosteroids Market Size - By Product (Glucocorticoids, Mineralocorticoids), Route of Administration (Topical, Injectable, Oral, Inhaled), Application (Skin Allergies, Rheumatology Indications), Distribution Channel & Forecast, 2024 - 2032 |
||||||
由于气喘、类风湿性关节炎和发炎性肠道疾病等慢性疾病的盛行率不断增加，预计 2024 年至 2032 年全球皮质类固醇市场规模的复合年增长率将达到 7.5%。皮质类固醇因其抗发炎和免疫抑制特性而被广泛使用，这使得它们在这些疾病的治疗中不可或缺。此外，老年人口的不断增长，加上生活方式的改变和环境因素，进一步导致皮质类固醇治疗的需求增加。根据世界卫生组织的统计，到2050年，60岁以上人口的比例将达到22%。
皮质类固醇市场根据产品、给药途径、应用、配销通路和地区进行分类。
以产品来看，盐皮质激素产品领域的产业规模到 2032 年可能会创下 6.8% 的复合年增长率，因为它在调节体内电解质平衡和体液量方面发挥关键作用。盐皮质激素，例如醛固酮，在维持血压和钠钾平衡方面发挥着至关重要的作用，这使得它们在治疗艾迪生氏病和先天性肾上腺增生等疾病中不可或缺。随着肾上腺功能不全及相关疾病的日益流行，预计未来几年对盐皮质激素的需求将激增。
在应用方面，内分泌领域的皮质类固醇产业预计2024年至2032年的复合年增长率为7.6%。增生。这些合成荷尔蒙模仿皮质醇（人体的天然压力荷尔蒙）的作用，有助于恢復荷尔蒙平衡和减轻与内分泌失调相关的症状。随着研究不断揭示内分泌疾病的复杂性，基于皮质类固醇的疗法的采用预计将稳步增长。
从地区来看，到2032 年，欧洲皮质类固醇市场规模将以7.4% 的复合年增长率增长，这归因于完善的医疗基础设施、高额医疗支出以及人们对皮质类固醇治疗益处的认识不断提高。此外，慢性呼吸道疾病和自体免疫疾病的盛行率不断上升，需要使用皮质类固醇来进行有效的疾病管理。此外，主要市场参与者为扩大其在欧洲国家的业务而采取的策略性倡议进一步促进了市场成长。
目录
第 1 章：方法与范围
第 2 章：执行摘要
第 3 章：产业洞察
- 产业生态系统分析
- 产业影响力
- 成长动力
- 药物配方的进步
- 慢性病发生率增加
- 研发投资激增
- 癌症盛行率不断上升
- 产业陷阱与挑战
- 与长期使用皮质类固醇相关的不良反应和副作用
- 政府对企业的定价压力
- 成长动力
- 成长潜力分析
- 监管环境
- 技术景观
- 波特的分析
- PESTEL分析
- 未来市场趋势
第 4 章：竞争格局
- 介绍
- 公司矩阵分析
- 公司市占率分析
- 竞争定位矩阵
- 战略仪表板
第 5 章：市场估计与预测：按产品分类，2018 年 - 2032 年
- 主要趋势
- 糖皮质激素
- 盐皮质激素
第 6 章：市场估计与预测：按管理途径，2018 年 - 2032 年
- 主要趋势
- 专题
- 可注射
- 口服
- 吸入
第 7 章：市场估计与预测：按应用分类，2018 年 - 2032 年
- 主要趋势
- 皮肤过敏
- 胃肠病学
- 内分泌科
- 急性呼吸道疾病
- 风湿病适应症
- 其他应用
第 8 章：市场估计与预测：按配销通路，2018 年 - 2032 年
- 主要趋势
- 医院药房
- 零售药局
- 网路药局
第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年
- 主要趋势
- 北美洲
- 我们
- 加拿大
- 欧洲
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 欧洲其他地区
- 亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
- 中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
- 中东和非洲其他地区
第 10 章：公司简介
- AbbVie Inc.
- Astellas Pharma Inc.
- AstraZeneca plc
- Bausch Health Companies Inc.
- Bayer AG
- Cipla Limited
- Eli Lilly and Company
- GlaxoSmithKline plc
- Lupin Limited
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi S.A
Global corticosteroids market size is anticipated to witness 7.5% CAGR from 2024 to 2032, due to the increasing prevalence of chronic ailments, such as asthma, rheumatoid arthritis, and inflammatory bowel diseases. Corticosteroids are widely prescribed for their anti-inflammatory and immunosuppressive properties, making them indispensable in the management of these conditions. Moreover, the growing geriatric population, coupled with lifestyle changes and environmental factors are further contributing to the escalating demand for corticosteroid-based therapies. As per the WHO stats, the population of 60 years and older will reach 22% by 2050.
The corticosteroids market is classified based on product, route of administration, application, distribution channel, and region.
By product, the industry size from the mineralocorticoids product segment may record 6.8% CAGR till 2032 owing to its pivotal role in regulating electrolyte balance and fluid volume in the body. Mineralocorticoids, such as aldosterone play a crucial role in maintaining blood pressure and sodium-potassium balance, making them indispensable in the treatment of conditions like Addison's disease and congenital adrenal hyperplasia. With the increasing prevalence of adrenal insufficiency and related disorders, the demand for mineralocorticoids is projected to surge in the coming years.
In terms of application, the corticosteroids industry from the endocrinology segment is predicted to witness 7.6% CAGR from 2024 to 2032. Corticosteroids find widespread application in the management of hormonal disorders, including adrenal insufficiency, Cushing's syndrome, and congenital adrenal hyperplasia. These synthetic hormones mimic the action of cortisol, the body's natural stress hormone, and are instrumental in restoring hormonal balance and alleviating symptoms associated with endocrine disorders. As research continues to unravel the complexities of endocrine diseases, the adoption of corticosteroid-based therapies is expected to witness a steady rise.
Regionally, the Europe corticosteroids market size will expand at 7.4% CAGR through 2032, attributed to the presence of a well-established healthcare infrastructure, high healthcare expenditure, and increasing awareness regarding the benefits of corticosteroid therapy. Moreover, the rising prevalence of chronic respiratory diseases and autoimmune disorders is necessitating the use of corticosteroids for effective disease management. Additionally, strategic initiatives undertaken by key market players to expand their presence in European countries are further augmenting market growth.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definition
- 1.2 Base estimates & calculations
- 1.3 Data collection
- 1.4 Forecast parameters
- 1.5 Data validation
- 1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
- 1.6.2.1 Paid sources
- 1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Advancements in drug formulations
- 3.2.1.2 Increasing incidence of chronic diseases
- 3.2.1.3 Surging investment in research and development
- 3.2.1.4 Growing prevalence of cancers
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Adverse reactions and side effects associated with prolonged use of Corticosteriods
- 3.2.2.2 Pricing pressure on the companies by government
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.6 Porter's analysis
- 3.6.1 Supplier power
- 3.6.2 Buyer power
- 3.6.3 Threat of new entrants
- 3.6.4 Threat of substitutes
- 3.6.5 Industry rivalry
- 3.7 PESTEL analysis
- 3.8 Future market trends
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Company market share analysis
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Glucocorticoids
- 5.3 Mineralocorticoids
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Topical
- 6.3 Injectable
- 6.4 Oral
- 6.5 Inhaled
Chapter 7 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Skin allergies
- 7.3 Gastroenterology
- 7.4 Endocrinology
- 7.5 Acute respiratory diseases
- 7.6 Rheumatology indications
- 7.7 Other applications
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospital pharmacies
- 8.3 Retail pharmacies
- 8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Italy
- 9.3.5 Spain
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 AbbVie Inc.
- 10.2 Astellas Pharma Inc.
- 10.3 AstraZeneca plc
- 10.4 Bausch Health Companies Inc.
- 10.5 Bayer AG
- 10.6 Cipla Limited
- 10.7 Eli Lilly and Company
- 10.8 GlaxoSmithKline plc
- 10.9 Lupin Limited
- 10.10 Merck & Co., Inc.
- 10.11 Novartis AG
- 10.12 Pfizer Inc.
- 10.13 Sanofi S.A
